DCB-R0237

N/A

Report date: 2026/05/13 20:02:10

NME

Base Information

Drug NameDCB-R0237

Drug Alias Namemultiple-kinase inhibitor (Development Center for Biotechnology)DCB-R0237

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsEpidermal growth factor receptor erbB1 inhibitorsVascular endothelial growth factor receptor 2 inhibitors

TargetsVascular endothelial growth factor receptor 2Epidermal growth factor receptor erbB1Serine/threonine-protein kinase B-raf

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDevelopment Center for Biotechnology

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDevelopment Center for Biotechnology

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A